Back to search results

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Clear Cell Renal Cell Carcinoma (ccRCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

  • Mayo Clinic, Phoenix, Arizona, United States

  • University of Arizona, Tucson, Arizona, United States

  • John Wayne Cancer Institute (JWCI), Santa Monica, California, United States

  • Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States

  • Yale University Hospital, New Haven, Connecticut, United States

  • Mayo Clinic Jacksonville, Jacksonville, Florida, United States

  • Moffitt Cancer Center - McKinley Drive, Tampa, Florida, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

  • Henry Ford Health, Detroit, Michigan, United States

  • Mayo Clinic, Rochester, Minnesota, United States

  • NYU Langone Health Perlmutter Cancer Center, New York, New York, United States

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Columbia University - The Trustees of Columbia University in the City of New York, New York, New York, United States

  • Montefiore Medical Center, New York, New York, United States

  • University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester, Rochester, New York, United States

  • James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

  • Providence Portland Medical Center, Portland, Oregon, United States

  • Oregon Health & Science University (3485 S. Bond), Portland, Oregon, United States

  • Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

  • Lifespan Cancer Institute, Providence, Rhode Island, United States

  • MD Anderson Cancer Center, Houston, Texas, United States

  • Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States

  • West Virginia University, Morgantown, West Virginia, United States

Study leads

  • Clinical Trials Management

    Study Director

    Regeneron Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)